NASDAQ:APVO Aptevo Therapeutics Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Aptevo Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $3.79 +0.21 (+5.87%) (As of 07/5/2022 02:10 PM ET) Add Compare Share Today's Range$3.61▼$3.9250-Day Range$3.26▼$5.6852-Week Range$3.03▼$22.68Volume449 shsAverage Volume144,020 shsMarket Capitalization$18.99 millionP/E RatioN/ADividend YieldN/APrice Target$28.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Aptevo Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside638.8% Upside$28.00 Price TargetShort InterestHealthy3.50% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.62Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($6.24) to ($5.47) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.1.50 out of 5 starsMedical Sector1000th out of 1,428 stocksPharmaceutical Preparations Industry490th out of 680 stocks 3.3 Analyst's Opinion Consensus RatingAptevo Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $28.00, Aptevo Therapeutics has a forecasted upside of 638.8% from its current price of $3.79.Amount of Analyst CoverageAptevo Therapeutics has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.50% of the outstanding shares of Aptevo Therapeutics have been sold short.Short Interest Ratio / Days to CoverAptevo Therapeutics has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aptevo Therapeutics has recently increased by 20.94%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAptevo Therapeutics does not currently pay a dividend.Dividend GrowthAptevo Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for APVO. Previous Next 2.0 News and Social Media Coverage News SentimentAptevo Therapeutics has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.80 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Aptevo Therapeutics this week, compared to 0 articles on an average week.Search InterestOnly 2 people have searched for APVO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aptevo Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.10% of the stock of Aptevo Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 33.64% of the stock of Aptevo Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Aptevo Therapeutics are expected to grow in the coming year, from ($6.24) to ($5.47) per share.Price to Book Value per Share RatioAptevo Therapeutics has a P/B Ratio of 15.16. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive APVO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aptevo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address About Aptevo Therapeutics (NASDAQ:APVO) StockAptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It also develoes APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.Read More APVO Stock News HeadlinesJuly 5, 2022 | americanbankingnews.comAptevo Therapeutics Inc. (NASDAQ:APVO) Short Interest UpdateJune 17, 2022 | msn.comAptevo Therapeutics's Return On Capital Employed OverviewJune 11, 2022 | seekingalpha.comAptevo gains after disclosing additional remission data in leukemia trialJune 9, 2022 | finance.yahoo.comAptevo Therapeutics Announces New Preliminary Remission Data on Four Additional Patients Enrolled in On-going APVO436 Dose Expansion Phase 1b Trial for the Treatment of Acute Myeloid LeukemiaMay 12, 2022 | finance.yahoo.comAptevo Therapeutics Reports First Quarter 2022 Financial Results and Business HighlightsApril 12, 2022 | finanznachrichten.deAptevo Therapeutics: APVO442 Prostate Cancer Data Presented at the American Association for Cancer Research Annual MeetingApril 12, 2022 | finance.yahoo.comAPVO442 Prostate Cancer Data Presented at the American Association for Cancer Research Annual MeetingMarch 30, 2022 | morningstar.comAptevo Therapeutics Announces Monotherapy Patient Received a Transplant in APVO436 Expansion Trial for the Treatment of Acute Myeloid Leukemia | MorningstarMarch 29, 2022 | finance.yahoo.comAptevo Therapeutics Announces Monotherapy Patient Received a Transplant in APVO436 Expansion Trial for the Treatment of Acute Myeloid LeukemiaMarch 24, 2022 | benzinga.comAptevo Therapeutics: Q4 Earnings InsightsMarch 24, 2022 | seekingalpha.comAptevo climbs as 2021 revenue more than doublesMarch 24, 2022 | msn.comWhy Did Aptevo Therapeutics Stock Jump 25% Today?March 24, 2022 | finance.yahoo.comAptevo Therapeutics Reports 2021 Financial Results and Provides Business UpdateFebruary 9, 2022 | benzinga.comAptevo Therapeutics Earns $10M Non-Dilutive Milestone Payment On Sales Of RUXIENCE, Provides Company UpdateFebruary 9, 2022 | seekingalpha.comAptevo Therapeutics receives $10M in non-dilutive milestone payment on RUXIENCE salesFebruary 9, 2022 | nasdaq.comAptevo Therapeutics Gains On Milestone Payment On Sale Of RuxienceFebruary 9, 2022 | finance.yahoo.comAptevo Therapeutics Earns $10 Million Non-Dilutive Milestone Payment on Sales of RUXIENCE, Provides Company UpdateJanuary 21, 2022 | seekingalpha.comAptevo Therapeutics Board Chairman Fuad El-Hibri to retireJanuary 21, 2022 | finance.yahoo.comAptevo Therapeutics' Board Chairman, Fuad El-Hibri, Announces Retirement, Effective April 1, 2022December 15, 2021 | finance.yahoo.comAlligator Bioscience & Aptevo Therapeutics Announce Co-Publication in Peer-Reviewed Journal, "Nature Communication"November 23, 2021 | msn.comAptevo Stock Rallies After Posting First Complete Remission In Early Acute Myeloid Leukemia TrialNovember 23, 2021 | finance.yahoo.comAptevo Therapeutics Reports First Complete Remission, Providing Clinical Update for Its Phase 1b Multi Center, Multi Cohort Expansion Trial in the Treatment of Acute Myeloid LeukemiaNovember 16, 2021 | benzinga.comAptevo Therapeutics Announces Presentation Of 2 Abstracts At Upcoming American Society Of Hematology Annual MeetingNovember 13, 2021 | benzinga.comAlligator Bioscience, Aptevo Therapeutics Announce Poster Presentation Of ALG.APV-527 At SITC Annual Meeting 2021November 12, 2021 | finance.yahoo.comAptevo Therapeutics Reports Third Quarter Financial Results With Business HighlightsSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:APVO CUSIPN/A CIK1671584 Webwww.aptevotherapeutics.com Phone(206) 838-0500Fax206-838-0503Employees54Year FoundedN/ACompany Calendar Last Earnings5/12/2022Today7/05/2022Next Earnings (Estimated)8/11/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$28.00 High Stock Price Forecast$36.00 Low Stock Price Forecast$20.00 Forecasted Upside/Downside+638.8%Consensus RatingModerate Buy Rating Score (0-4)2.5 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-28,460,000.00 Net Margins-222.55% Pretax Margin-228.05% Return on Equity-717.67% Return on Assets-49.92% Debt Debt-to-Equity Ratio3.05 Current Ratio1.75 Quick Ratio1.75 Sales & Book Value Annual Sales$12.29 million Price / Sales1.54 Cash FlowN/A Price / Cash FlowN/A Book Value$0.25 per share Price / Book15.16Miscellaneous Outstanding Shares5,010,000Free Float4,802,000Market Cap$18.99 million OptionableOptionable Beta6.14 Aptevo Therapeutics Frequently Asked Questions Should I buy or sell Aptevo Therapeutics stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aptevo Therapeutics in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Aptevo Therapeutics stock. View analyst ratings for Aptevo Therapeutics or view top-rated stocks. What is Aptevo Therapeutics' stock price forecast for 2022? 2 equities research analysts have issued 1-year price targets for Aptevo Therapeutics' shares. Their APVO stock forecasts range from $20.00 to $36.00. On average, they anticipate Aptevo Therapeutics' stock price to reach $28.00 in the next year. This suggests a possible upside of 638.8% from the stock's current price. View analysts' price targets for Aptevo Therapeutics or view top-rated stocks among Wall Street analysts. How has Aptevo Therapeutics' stock price performed in 2022? Aptevo Therapeutics' stock was trading at $7.87 on January 1st, 2022. Since then, APVO shares have decreased by 51.8% and is now trading at $3.79. View the best growth stocks for 2022 here. When is Aptevo Therapeutics' next earnings date? Aptevo Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022. View our earnings forecast for Aptevo Therapeutics. How were Aptevo Therapeutics' earnings last quarter? Aptevo Therapeutics Inc. (NASDAQ:APVO) announced its quarterly earnings results on Thursday, May, 12th. The biotechnology company reported ($1.59) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.15) by $0.44. The biotechnology company earned $3.11 million during the quarter, compared to analyst estimates of $3.75 million. Aptevo Therapeutics had a negative trailing twelve-month return on equity of 717.67% and a negative net margin of 222.55%. View Aptevo Therapeutics' earnings history. Who are Aptevo Therapeutics' key executives? Aptevo Therapeutics' management team includes the following people: Mr. Marvin L. White, Pres, CEO & Director (Age 60, Pay $870.65k)Mr. Jeffrey G. Lamothe CA, Exec. VP & CFO (Age 56, Pay $590.56k)Ms. SoYoung Kwon J.D., LL.M., Sr. VP, Gen. Counsel, Corp. Affairs & HRDr. Fatih M. Uckun M.D., Ph.D., Chief Clinical Advisor & Consultant Who are some of Aptevo Therapeutics' key competitors? Some companies that are related to Aptevo Therapeutics include Akebia Therapeutics (AKBA), Magenta Therapeutics (MGTA), MEI Pharma (MEIP), Bolt Biotherapeutics (BOLT), Reneo Pharmaceuticals (RPHM), FoxWayne Enterprises Acquisition (FOXW), Gemini Therapeutics (GMTX), Equillium (EQ), Lipocine (LPCN), Qilian International Holding Group (QLI), Synlogic (SYBX), Genprex (GNPX), Verrica Pharmaceuticals (VRCA), NightHawk Biosciences (NHWK) and Medicenna Therapeutics (MDNA). View all of APVO's competitors. What other stocks do shareholders of Aptevo Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aptevo Therapeutics investors own include Advanced Micro Devices (AMD), Amarin (AMRN), AVEO Pharmaceuticals (AVEO), Alibaba Group (BABA), Micron Technology (MU), OPKO Health (OPK), AbbVie (ABBV), Aurinia Pharmaceuticals (AUPH), BioXcel Therapeutics (BTAI) and T2 Biosystems (TTOO). What is Aptevo Therapeutics' stock symbol? Aptevo Therapeutics trades on the NASDAQ under the ticker symbol "APVO." How do I buy shares of Aptevo Therapeutics? Shares of APVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Aptevo Therapeutics' stock price today? One share of APVO stock can currently be purchased for approximately $3.79. How much money does Aptevo Therapeutics make? Aptevo Therapeutics (NASDAQ:APVO) has a market capitalization of $18.99 million and generates $12.29 million in revenue each year. How many employees does Aptevo Therapeutics have? Aptevo Therapeutics employs 54 workers across the globe. How can I contact Aptevo Therapeutics? Aptevo Therapeutics' mailing address is 2401 4TH AVENUE SUITE 1050, SEATTLE WA, 98121. The official website for Aptevo Therapeutics is www.aptevotherapeutics.com. The biotechnology company can be reached via phone at (206) 838-0500, via email at jurchisons@apvo.com, or via fax at 206-838-0503. This page (NASDAQ:APVO) was last updated on 7/5/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
